Alzchem Group AG

Alzchem Group AG seamlessly builds on strong business performance in 2023 with EBITDA growth of 31.7% in first quarter 2024

Alzchem Group AG: Bekanntmachung der Einberufung zur Hauptversammlung am 07.05.2024 in Trostberg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Alzchem Group AG: Alzchem Group AG receives EUR 34.4 million in EU funding

Crearene AG and Alzchem Group AG: Successful addition of creatine to dialysis patient treatments

Alzchem Group AG: EBITDA increase of 32.4 % to EUR 81.4 million – continuing on the road to success

Alzchem Group AG: Long-Covid: New clinical studies show high efficacy of creatine supplementation

Alzchem Group AG awarded for sustainable supply chains: Outstanding result certified by ‘Together for Sustainability (TfS)’ initiative

Alzchem Group AG expands Management Board: Supervisory Board appoints Andreas Lösler as new CFO with effect from 1 January 2024

Alzchem Group AG significantly increases EBITDA by 19.8% to EUR 56.3 million in the nine-month period 2023

Alzchem Group AG raises EBITDA forecast into the range of EUR 80 million for fiscal year 2023 despite slightly lower sales expectation

Alzchem Group AG: Creatine product ‘Creavitalis’: Wholesome taste and positive benefits for vegetarian and vegan foods

Alzchem Group AG reports positive business development in the first half of 2023

Alzchem Group AG ensures continuity on the Management Board: Contract extension with CEO Andreas Niedermaier until 2026

Alzchem Group AG: Annual General Meeting resolves increased dividend of EUR 1.05 per share – broad approval of all agenda items, including the climate roadmap

Alzchem Group AG achieves significant sales and earnings growth in the first quarter of 2023

Alzchem Group AG: Bekanntmachung der Einberufung zur Hauptversammlung am 11.05.2023 in Trostberg mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG

Alzchem Group AG: Alzchem Group AG achieves highest sales in the company’s history in the fiscal year 2022 with EUR 542.2 million (+28.4%)

Alzchem Group AG with strong sales growth of 31.4% in the 9-month period 2022

Alzchem and Crearene Develop Treatments for the Dialysis Market

Alzchem Group AG increases sales by 25.3% in the first half of 2022

Annual General Meeting 2022 of Alzchem Group AG: Broad shareholder approval for growth course and dividend increase

Alzchem Group AG: Early contract extension with CSO Dr. Georg Weichselbaumer and COO Klaus Englmaier

Alzchem Group AG achieves record sales of EUR 129.4 million (+24%) in the first quarter of 2022